Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.

…read more

Source: UPDATED: Bristol-Myers dominates–and disappoints–at ASCO immuno-oncology debut


0 No comments